No abstract

Objective To assess the rate of, and risk factors for, human cytomegalovirus viremia (HCMV) in donor+/recipient+ (HCMV serostatus matched) hematopoietic stem-cell transplantation (HSCT) recipients. Methods HCMV DNA from 144 donor+/recipient+ HSCT recipients was examined by quantitative polymerase chain reaction (qPCR). Results The cumulative incidence of HCMV viremia was 69.4% (100/144) during the 48 weeks after HSCT. In a multivariate analysis, acute graft-versus-host disease (aGVHD) was discovered to be a risk factor for the occurrence of HCMV viremia (P = .006). The cumulative incidence of HCMV viremia and increasing DNA loads were significantly associated with aGVHD occurrence (P = .001 for each). The occurrence of late-term HCMV viremia was associated with aGVHD (P = .001) and a higher DNA load during the first 12 weeks after HSCT (P = .04). Conclusions aGVHD is a risk factor for HCMV viremia. Recipients with aGVHD who have a high HCMV DNA load should be strictly monitored to prevent HCMV activation.

Since the 1980s, enterprise management has entered the stage of value management with the goal of maximizing enterprise value. In order to achieve the goal of maximizing value, companies must compete. Therefore, how to continuously enhance the competitiveness of enterprises to maximize the value of enterprises is a major issue that enterprise managers must seriously consider. Based on whether it shows competitive advantage, this paper divides enterprise competitiveness into revealed competitiveness and dynamic capabilities. By constructing multiple linear regression models, we study the impact o f revealed competitiveness and dynamic capabilities on enterprise value. The empirical results show that both revealed competitiveness and dynamic capabilities can positively affect enterprise value, but environmental dynamism will weaken the impact of both on enterprise value.